Plaque progression and regression in atherothrombosis

被引:45
作者
Ibanez, B. [1 ]
Vilahur, G. [1 ]
Badimon, J. J. [1 ]
机构
[1] Mt Sinai Sch Med, Zena & Michael A Wiener Cardiovasc Inst, New York, NY 10029 USA
关键词
D O I
10.1111/j.1538-7836.2007.02483.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Atherosclerotic disease is a pathological process characterized by the deposition of lipid and other blood-borne material within the arterial wall. The deposition of these materials and the subsequent thickening of the wall may significantly compromise the vessel lumen. Atherosclerosis is a diffuse disease with focal clinical manifestations that are the consequence of thrombotic complications on disrupted atherosclerotic lesions. Until recently, atherosclerosis development was envisaged as an incessant progressing process; however, new evidence has shown that atherosclerotic plaque homeostasis is not necessarily a constantly progressing process. There are many data showing that atherosclerotic plaque formation can be slowed, stopped or even reversed. Comprehension of the underlying mechanisms involved in the homeostasis of atherosclerotic plaque (progression/regression) should allow the development of interventions enhancing the regression pathway. Novel imaging technology has allowed the accurate evaluation of plaque progression, vital in the assessment of the efficacy of interventions. In this review we discuss the processes involved in the formation and progression of atherosclerotic lesions, the triggers for plaque disruption, as well as new therapies. We also deal with the potential pathways of plaque regression, as well as tools for accurate serial atherosclerotic quantification.
引用
收藏
页码:292 / 299
页数:8
相关论文
共 30 条
  • [1] Influence of lipid-lowering therapy on the progression of coronary artery calcification - A prospective evaluation
    Achenbach, S
    Ropers, D
    Pohle, K
    Leber, A
    Thilo, C
    Knez, A
    Menendez, T
    Maeffert, R
    Kusus, M
    Regenfus, M
    Bickel, A
    Haberl, R
    Steinbeck, G
    Moshage, W
    Daniel, WG
    [J]. CIRCULATION, 2002, 106 (09) : 1077 - 1082
  • [2] BADIMON JJ, 1989, LAB INVEST, V60, P455
  • [3] Intensive versus moderate lipid lowering with statins after acute coronary syndromes
    Cannon, CP
    Braunwald, E
    McCabe, CH
    Rader, DJ
    Rouleau, JL
    Belder, R
    Joyal, SV
    Hill, KA
    Pfeffer, MA
    Skene, AM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (15) : 1495 - 1504
  • [4] The role of high-density lipoprotein cholesterol in the prevention and possible treatment of cardiovascular diseases
    Choi, B. G.
    Vilahur, G.
    Yadegar, D.
    Viles-Gonzalez, J. F.
    Badimon, J. J.
    [J]. CURRENT MOLECULAR MEDICINE, 2006, 6 (05) : 571 - 587
  • [5] Effects of lipid-lowering by simvastatin on human atherosclerotic lesions - A longitudinal study by high-resolution, noninvasive magnetic resonance imaging
    Corti, R
    Fayad, ZA
    Fuster, V
    Worthley, SG
    Helft, G
    Chesebro, J
    Mercuri, M
    Badimon, JJ
    [J]. CIRCULATION, 2001, 104 (03) : 249 - 252
  • [6] Lipid lowering by simvastatin induces regression of human atherosclerotic lesions - Two years' follow-up by high-resolution noninvasive magnetic resonance imaging
    Corti, R
    Fuster, V
    Fayad, ZA
    Worthley, SG
    Helft, G
    Smith, D
    Weinberger, J
    Wentzel, J
    Mizsei, G
    Mercuri, M
    Badimon, JJ
    [J]. CIRCULATION, 2002, 106 (23) : 2884 - 2887
  • [7] Fenofibrate induces plaque regression in hypercholesterolemic atherosclerotic rabbits: In vivo demonstration by high-resolution MRI
    Corti, Roberto
    Osende, Julio
    Hutter, Randolph
    Viles-Gonzalez, Juan F.
    Zafar, Urooj
    Valdivieso, Carolina
    Mizsei, Gabor
    Fallon, John T.
    Fuster, Valentin
    Badimon, Juan J.
    [J]. ATHEROSCLEROSIS, 2007, 190 (01) : 106 - 113
  • [8] Macrophage reverse cholesterol transport - Key to the regression of atherosclerosis?
    Cuchel, Marina
    Rader, Daniel J.
    [J]. CIRCULATION, 2006, 113 (21) : 2548 - 2555
  • [9] Measurement of arterial wall thickness as a surrogate marker for atherosclerosis
    de Groot, E
    Hovingh, GK
    Wiegman, A
    Duriez, P
    Smit, AJ
    Fruchart, JC
    Kastelein, JJP
    [J]. CIRCULATION, 2004, 109 (23) : 33 - 38
  • [10] A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement:: the BISTRO II randomized trial
    Eriksson, BI
    Dahl, OE
    Büller, HR
    Hettiarachchi, R
    Rosencher, N
    Bravo, ML
    Ahnfelt, L
    Piovella, F
    Stangier, J
    Kälebo, P
    Reilly, P
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (01) : 103 - 111